Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT04214288 2025-11-20

SERENA-2

Phase 2 Active not recruiting

240 enrolled 16 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT02107703 2025-10-21

MONARCH 2

Phase 3 Active not recruiting

669 enrolled 22 charts 1 FDA

Breast

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2 Active not recruiting

220 enrolled 11 charts

Breast

Breast Neoplasms

NCT03939897 2025-09-24

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Phase 1 Active not recruiting

24 enrolled 15 charts

Breast

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 3 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Phase 2 Active not recruiting

61 enrolled 12 charts

Breast

Breast Neoplasms

Clinical Trials

FINER

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

CONFIRM

VERITAC-2

INAVO120

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

PATINA

MONARCH plus

CAPItello-291

postMONARCH

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

SERENA-2

MONARCH 2

Palbociclib After CDK and Endocrine Therapy (PACE)

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

EMBER-3

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer